These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38378856)

  • 21. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial.
    Toback S; Galiza E; Cosgrove C; Galloway J; Goodman AL; Swift PA; Rajaram S; Graves-Jones A; Edelman J; Burns F; Minassian AM; Cho I; Kumar L; Plested JS; Rivers EJ; Robertson A; Dubovsky F; Glenn G; Heath PT;
    Lancet Respir Med; 2022 Feb; 10(2):167-179. PubMed ID: 34800364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity.
    Budimir N; Huckriede A; Meijerhof T; Boon L; Gostick E; Price DA; Wilschut J; de Haan A
    PLoS One; 2012; 7(1):e30898. PubMed ID: 22303469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection.
    Nagai M; Moriyama M; Ichinohe T
    mBio; 2021 Aug; 12(4):e0159821. PubMed ID: 34399617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations.
    Hessel A; Schwendinger M; Fritz D; Coulibaly S; Holzer GW; Sabarth N; Kistner O; Wodal W; Kerschbaum A; Savidis-Dacho H; Crowe BA; Kreil TR; Barrett PN; Falkner FG
    PLoS One; 2010 Aug; 5(8):e12217. PubMed ID: 20808939
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
    Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
    Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 4 clinical trials in the era of the Coronavirus Disease (COVID-19) pandemic and their importance to optimize the COVID-19 vaccination.
    Ralise AEG; Camargo TM; Marson FAL
    Hum Vaccin Immunother; 2023 Aug; 19(2):2234784. PubMed ID: 37449956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inactivated whole influenza virus particle vaccines induce neutralizing antibodies with an increase in immunoglobulin gene subclones of B-lymphocytes in cynomolgus macaques.
    Shiohara M; Suzuki S; Shichinohe S; Ishigaki H; Nakayama M; Nomura N; Shingai M; Sekiya T; Ohno M; Iida S; Kawai N; Kawahara M; Yamagishi J; Ito K; Mitsumata R; Ikeda T; Motokawa K; Sobue T; Kida H; Ogasawara K; Itoh Y
    Vaccine; 2022 Jun; 40(30):4026-4037. PubMed ID: 35641357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coinfection by Severe Acute Respiratory Syndrome Coronavirus 2 and Influenza A(H1N1)pdm09 Virus Enhances the Severity of Pneumonia in Golden Syrian Hamsters.
    Zhang AJ; Lee AC; Chan JF; Liu F; Li C; Chen Y; Chu H; Lau SY; Wang P; Chan CC; Poon VK; Yuan S; To KK; Chen H; Yuen KY
    Clin Infect Dis; 2021 Jun; 72(12):e978-e992. PubMed ID: 33216851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and safety of the quadrivalent inactivated split-virion influenza vaccine in populations aged ≥ 3 years: A phase 3, randomized, double-blind, non-inferiority clinical trial.
    Chen J; Jiang F; Zhao C; Chai J; Li L; Guan Q; Li X; Wang F; Li A; Gao H; Wang M; Fu L; Nie F; Ling W; Deng H; Zhou L
    Hum Vaccin Immunother; 2023 Aug; 19(2):2245721. PubMed ID: 37587615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
    He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
    Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Technical guidelines for seasonal influenza vaccination in China (2020-2021)].
    National Immunization Advisory Committee Technical Working Group
    Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Oct; 54(10):1035-1059. PubMed ID: 33131228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine.
    Furuyama W; Shifflett K; Pinski AN; Griffin AJ; Feldmann F; Okumura A; Gourdine T; Jankeel A; Lovaglio J; Hanley PW; Thomas T; Clancy CS; Messaoudi I; O'Donnell KL; Marzi A
    mBio; 2022 Feb; 13(1):e0337921. PubMed ID: 35012339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial.
    Nicholson KG; Abrams KR; Batham S; Clark TW; Hoschler K; Lim WS; Medina MJ; Nguyen-Van-Tam JS; Read RC; Warren FC; Zambon M
    Lancet Infect Dis; 2011 Feb; 11(2):91-101. PubMed ID: 21168369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season.
    Grohskopf LA; Alyanak E; Ferdinands JM; Broder KR; Blanton LH; Talbot HK; Fry AM
    MMWR Recomm Rep; 2021 Aug; 70(5):1-28. PubMed ID: 34448800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of A/H1N1/2009 split inactivated influenza A vaccine (GC1115) in mice and ferrets.
    Han HJ; Song MS; Park SJ; Byun HY; Robles NJC; Ha SH; Choi YK
    J Microbiol; 2019 Feb; 57(2):163-169. PubMed ID: 30706345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of gamma-irradiation conditions on the immunogenicity of whole-inactivated Influenza A virus vaccine.
    David SC; Lau J; Singleton EV; Babb R; Davies J; Hirst TR; McColl SR; Paton JC; Alsharifi M
    Vaccine; 2017 Feb; 35(7):1071-1079. PubMed ID: 28109709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rational design of an influenza-COVID-19 chimeric protective vaccine with HA-stalk and S-RBD.
    Li Y; Liu P; Hao T; Liu S; Wang X; Xie Y; Xu K; Lei W; Zhang C; Han P; Li Y; Jin X; Huan Y; Lu Y; Zhang R; Li X; Zhao X; Xu K; Liao P; Lu X; Bi Y; Song H; Wu G; Zhu B; Gao GF
    Emerg Microbes Infect; 2023 Dec; 12(2):2231573. PubMed ID: 37394992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trivalent inactivated influenza vaccine response and immunogenicity assessment after one week and three months in repeatedly vaccinated adults.
    Tawfik A; Kawaguchi T; Takahashi M; Setoh K; Yamaguchi I; Tabara Y; Van Steen K; Sakuntabhai A; Matsuda F
    Expert Rev Vaccines; 2023; 22(1):826-838. PubMed ID: 37747798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy.
    Ottóffy G; Horváth P; Muth L; Sólyom A; Garami M; Kovács G; Nyári T; Molnár D; Pauler G; Jankovics I
    Pediatr Blood Cancer; 2014 Jun; 61(6):1013-6. PubMed ID: 24395342
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing the pyrogenicity of whole influenza virus particle vaccine in cynomolgus macaques.
    Ohno M; Sagata M; Sekiya T; Nomura N; Shingai M; Endo M; Kimachi K; Suzuki S; Thanh Nguyen C; Nakayama M; Ishigaki H; Ogasawara K; Itoh Y; Kino Y; Kida H
    Vaccine; 2023 Jan; 41(3):787-794. PubMed ID: 36526501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.